Publication Name	World Journal of Clinical Oncology
Manuscript ID	8572
Country	Japan

Received	2013-12-29 16:48
Peer-Review Started	2013-12-29 18:11
First Decision by Editorial Office Director
Return for Revision	2014-02-20 23:47
Revised	2014-02-28 10:21
Publication Fee Transferred
Second Decision by Editor	2014-05-16 17:29
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2014-05-16 17:50
Articles in Press	2014-05-23 09:11
Edit the Manuscript by Language Editor	2014-05-22 14:01
Typeset the Manuscript	2014-07-24 14:18
Publish the Manuscript Online	2014-08-01 16:16

ISSN	2218-4333 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Topic Highlights
Article Title	Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer
Manuscript Source	Invited Manuscript
All Author List	Kazuhiro Asami and Shinji Atagi
Funding Agency and Grant Number
Corresponding Author	Kazuhiro Asami, MD, Department of Clinical Oncology, National Hospital Organization Kinki-chuo Chest Medical Center, 1180 Nagasone-cho Kita-ku, Sakai City, Osaka 591-8555, Japan. kazu.taizo@nifty.com
Key Words	Epidermal growth factor receptor mutation; Epidermal growth factor receptor tyrosine kinase inhibitors; Non-small cell lung cancer; Secondary resistance
Core Tip	Although gefitinib and erlotinib provide a significant response and survival benefit, all responders eventually acquire resistance. Second-generation epidermal growth factor receptor (EGFR)-targeting agents, such as afatinib and dacomitinib, may improve survival further and be useful for patients who acquired resistance to ?rst-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). This review discusses novel therapeutic strategies for EGFR-mutated advanced non-small cell lung cancer using first- and second-generation EGFR-TKIs.
Publish Date	2014-08-01 16:16
Citation	Asami K, Atagi S. Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer. World J Clin Oncol 2014; 5(4): 646-659
URL	http://www.wjgnet.com/2218-4333/full/v5/i4/646.htm
DOI	http://dx.doi.org/10.5306/wjco.v5.i4.646

Full Article (PDF)	WJCO-5-646.pdf
Full Article (Word)	WJCO-5-646.doc
Manuscript File	8572-Review.docx
Answering Reviewers	8572-Answering reviewers.pdf
Copyright License Agreement	8572-Copyright assignment.pdf
Peer-review Report	8572-Peer review(s).pdf
Scientific Editor Work List	8572-Scientific editor work list.pdf